- Home
- RELY vs AKRO Comparison
RELY vs AKRO Comparison
Compare RELY & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELY
- AKRO
- Stock Information
- Founded
- RELY 2011
- AKRO 2017
- Country
- RELY United States
- AKRO United States
- Employees
- RELY N/A
- AKRO N/A
- Industry
- RELY Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RELY Technology
- AKRO Health Care
- Exchange
- RELY Nasdaq
- AKRO Nasdaq
- Market Cap
- RELY 4.6B
- AKRO 3.9B
- IPO Year
- RELY 2021
- AKRO 2019
- Fundamental
- Price
- RELY $18.31
- AKRO $51.91
- Analyst Decision
- RELY Buy
- AKRO Strong Buy
- Analyst Count
- RELY 10
- AKRO 6
- Target Price
- RELY $27.40
- AKRO $82.50
- AVG Volume (30 Days)
- RELY 3.5M
- AKRO 1.7M
- Earning Date
- RELY 07-30-2025
- AKRO 08-08-2025
- Dividend Yield
- RELY N/A
- AKRO N/A
- EPS Growth
- RELY N/A
- AKRO N/A
- EPS
- RELY N/A
- AKRO N/A
- Revenue
- RELY $1,356,469,000.00
- AKRO N/A
- Revenue This Year
- RELY $27.85
- AKRO N/A
- Revenue Next Year
- RELY $20.42
- AKRO N/A
- P/E Ratio
- RELY N/A
- AKRO N/A
- Revenue Growth
- RELY 34.37
- AKRO N/A
- 52 Week Low
- RELY $12.33
- AKRO $21.34
- 52 Week High
- RELY $27.32
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RELY 34.70
- AKRO 49.81
- Support Level
- RELY $18.04
- AKRO $50.57
- Resistance Level
- RELY $18.83
- AKRO $52.73
- Average True Range (ATR)
- RELY 0.74
- AKRO 1.97
- MACD
- RELY -0.09
- AKRO -0.80
- Stochastic Oscillator
- RELY 6.82
- AKRO 19.76
About RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.